↓ Skip to main content

Endocannabinoids

Overview of attention for book
Attention for Chapter 8: Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news
1 news outlet
twitter
10 X users
facebook
1 Facebook page
googleplus
1 Google+ user
reddit
1 Redditor

Readers on

mendeley
274 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Chapter number 8
Book title
Endocannabinoids
Published in
Handbook of experimental pharmacology, January 2015
DOI 10.1007/978-3-319-20825-1_8
Pubmed ID
Book ISBNs
978-3-31-920824-4, 978-3-31-920825-1
Authors

Fernández-Ruiz, Javier, Romero, Julián, Ramos, José A, Javier Fernández-Ruiz, Julián Romero, José A. Ramos

Editors

Roger G. Pertwee

Abstract

This review focuses on the role of the endocannabinoid signaling system in controlling neuronal survival, an extremely important issue to be considered when developing new therapies for neurodegenerative disorders. First, we will describe the cellular and molecular mechanisms, and the signaling pathways, underlying these neuroprotective properties, including the control of glutamate homeostasis, calcium influx, the toxicity of reactive oxygen species, glial activation and other inflammatory events; and the induction of autophagy. We will then concentrate on the preclinical studies and the few clinical trials that have been carried out targeting endocannabinoid signaling in three important chronic progressive neurodegenerative disorders (Parkinson's disease, Huntington's chorea, and Alzheimer's disease), as well as in other less well-studied disorders. We will end by offering some ideas and proposals for future research that should be carried out to optimize endocannabinoid-based treatments for these disorders. Such studies will strengthen the possibility that these therapies will be investigated in the clinical scenario and licensed for their use in specific disorders.

X Demographics

X Demographics

The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 274 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 2 <1%
United States 1 <1%
Brazil 1 <1%
Unknown 270 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 49 18%
Student > Ph. D. Student 48 18%
Student > Master 34 12%
Researcher 26 9%
Student > Doctoral Student 15 5%
Other 40 15%
Unknown 62 23%
Readers by discipline Count As %
Medicine and Dentistry 39 14%
Neuroscience 36 13%
Biochemistry, Genetics and Molecular Biology 30 11%
Agricultural and Biological Sciences 28 10%
Pharmacology, Toxicology and Pharmaceutical Science 21 8%
Other 54 20%
Unknown 66 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2017.
All research outputs
#2,168,413
of 25,257,066 outputs
Outputs from Handbook of experimental pharmacology
#77
of 684 outputs
Outputs of similar age
#29,325
of 364,783 outputs
Outputs of similar age from Handbook of experimental pharmacology
#13
of 69 outputs
Altmetric has tracked 25,257,066 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 684 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,783 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.